Clinical Trials
3 trialsNCT04204057 2024-08-13
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Rhizen Pharmaceuticals SA
Phase 2 Completed
NCT03711604 2024-05-08
Compassionate Use Study of Tenalisib (RP6530)
Rhizen Pharmaceuticals SA
Phase 1/2 Completed
NCT02017613 2016-06-24
PI3K
Rhizen Pharmaceuticals SA
Phase 1 Completed